Fundraising Fox
/Companies
Sign in

AyuVis Research

Fort Worth, US · Founded 2018 · Texas corporation

Find your way into AyuVis Research

Sign up to see every warm intro you have to AyuVis Research

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the AyuVis Research team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

AyuVis develops novel small-molecule immunotherapies with a unique mode of action to fight inflammation and infection. Founded in 2014, the company focuses on drug discovery and clinical development in areas including neonatal immunology and infectious disease.

BiotechHealthtechMedical Devices

Founders & leadership

AyuVis Research was founded in 2018 by Suchi Acharya.

SASuchi Acharya
Suchi AcharyaFounder and CEOSuchi Acharya is founder and CEO of AyuVis Research, which develops small-molecule immunotherapies for inflammatory and infectious diseases. She brings expertise in biochemistry and chemical biology, and has led the company's drug discovery and clinical development efforts since its founding in 2014.
DR
David RileyChief Medical Officer
DD
Dennis DeanHead of CMC
DC
Dale ChristensenDirector of Early Development
GA
Gagan AcharyaNamed on SEC filing
SM
Stella M RobertsonNamed on SEC filing

Reported raises · per SEC filings

Form D private placements

$2M disclosed across 2 rounds · 2018–2019

▶$745KraisedOct 2019 · 17 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Gagan AcharyaDirector
  • Stella M RobertsonDirector
  • Dwight HortonExecutive Officer
  • Beamon AgarwalExecutive Officer
  • William Dennis DeanExecutive Officer
  • Suchismita AcharyaExecutive Officer, Director
  • Russell BromleyExecutive Officer
Offering amount
$750K
Amount sold
$745K
Proceeds to insiders
$60K
First sale
Apr 2019
Incorporated
Corporation, Texas, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.3MraisedApr 2019 · 26 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Suchismita AcharyaExecutive Officer, Director
  • Gagan AcharyaExecutive Officer, Director
  • Stella M RobertsonDirector
Offering amount
$1.3M
Amount sold
$1.3M
Proceeds to insiders
$60K
First sale
Apr 2018
Incorporated
Corporation, Texas, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2022$2M
National Institutes of Health (NIH)National Institutes of HealthPhase I2017$273.8K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does AyuVis Research do?
AyuVis develops novel small-molecule immunotherapies with a unique mode of action to fight inflammation and infection. Founded in 2014, the company focuses on drug discovery and clinical development in areas including neonatal immunology and infectious disease.
Who founded AyuVis Research?
AyuVis Research was founded by Suchi Acharya in 2018.
How much funding has AyuVis Research raised?
AyuVis Research has disclosed $2M raised across 2 rounds.
Where is AyuVis Research headquartered?
AyuVis Research is headquartered in Fort Worth, US.